
|Articles|January 1, 2004
Combination kills cancer
New York - Results from the largest-ever phase III trial in advanced metastatic melanoma, while preliminary, suggest dacarbazine (DTIC) plus an investigational antisense compound (oblimersen sodium, or Genasense) may significantly improve overall survival versus DTIC alone, according to Anna C. Pavlick, D.O.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
3
ICYMI: First Patient Dosed in Global Phase 2 Study of Oral TYK2 Inhibitor Soficitinib for PN
4
Dermatology Conferences and Meetings Calendar: December 2025
5


















